These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


424 related items for PubMed ID: 21527066

  • 1. Chemokine axes CXCL12/CXCR4 and CXCL16/CXCR6 correlate with lymph node metastasis in epithelial ovarian carcinoma.
    Guo L, Cui ZM, Zhang J, Huang Y.
    Chin J Cancer; 2011 May; 30(5):336-43. PubMed ID: 21527066
    [Abstract] [Full Text] [Related]

  • 2. Expression of the CXCL12/CXCR4 and CXCL16/CXCR6 axes in cervical intraepithelial neoplasia and cervical cancer.
    Huang Y, Zhang J, Cui ZM, Zhao J, Zheng Y.
    Chin J Cancer; 2013 May; 32(5):289-96. PubMed ID: 22958742
    [Abstract] [Full Text] [Related]

  • 3. CXCL16 and CXCR6 are coexpressed in human lung cancer in vivo and mediate the invasion of lung cancer cell lines in vitro.
    Hu W, Liu Y, Zhou W, Si L, Ren L.
    PLoS One; 2014 May; 9(6):e99056. PubMed ID: 24897301
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. CXCR6 is expressed in human prostate cancer in vivo and is involved in the in vitro invasion of PC3 and LNCap cells.
    Hu W, Zhen X, Xiong B, Wang B, Zhang W, Zhou W.
    Cancer Sci; 2008 Jul; 99(7):1362-9. PubMed ID: 18452560
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Irradiation of breast cancer cells enhances CXCL16 ligand expression and induces the migration of natural killer cells expressing the CXCR6 receptor.
    Yoon MS, Pham CT, Phan MT, Shin DJ, Jang YY, Park MH, Kim SK, Kim S, Cho D.
    Cytotherapy; 2016 Dec; 18(12):1532-1542. PubMed ID: 27720639
    [Abstract] [Full Text] [Related]

  • 9. Clinical significance of CXCL16/CXCR6 expression in patients with prostate cancer.
    Ha HK, Lee W, Park HJ, Lee SD, Lee JZ, Chung MK.
    Mol Med Rep; 2011 Dec; 4(3):419-24. PubMed ID: 21468586
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The chemokine receptor CXCR6 and its ligand CXCL16 are expressed in carcinomas and inhibit proliferation.
    Meijer J, Ogink J, Kreike B, Nuyten D, de Visser KE, Roos E.
    Cancer Res; 2008 Jun 15; 68(12):4701-8. PubMed ID: 18559516
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Role of CXCL16/CXCR6 axis in the metastasis of human prostate cancer].
    Zhou WH, Hu WD, Wu ZQ, Zheng XM, Wang BC.
    Zhonghua Yi Xue Za Zhi; 2010 Apr 13; 90(14):947-51. PubMed ID: 20646641
    [Abstract] [Full Text] [Related]

  • 16. Expression and localization of CXCL16 and CXCR6 in ovarian endometriotic tissues.
    Manabe S, Iwase A, Goto M, Kobayashi H, Takikawa S, Nagatomo Y, Nakahara T, Bayasula, Nakamura T, Hirokawa W, Kikkawa F.
    Arch Gynecol Obstet; 2011 Dec 13; 284(6):1567-72. PubMed ID: 21773780
    [Abstract] [Full Text] [Related]

  • 17. The prognostic significance of CXCL16 and its receptor C-X-C chemokine receptor 6 in prostate cancer.
    Richardsen E, Ness N, Melbø-Jørgensen C, Johannesen C, Grindstad T, Nordbakken C, Al-Saad S, Andersen S, Dønnem T, Nordby Y, Bremnes RM, Busund LT.
    Am J Pathol; 2015 Oct 13; 185(10):2722-30. PubMed ID: 26272362
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. CXCR6-CXCL16 axis promotes prostate cancer by mediating cytoskeleton rearrangement via Ezrin activation and αvβ3 integrin clustering.
    Singh R, Kapur N, Mir H, Singh N, Lillard JW, Singh S.
    Oncotarget; 2016 Feb 09; 7(6):7343-53. PubMed ID: 26799186
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]


    Page: [Next] [New Search]
    of 22.